Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials

Annals of Thoracic Surgery

Volumn 62, Issue 5, 1996, Pages 1404-1411

  Usui, Akihiko ^a,b   Hiroura, Manabu ^a   Kawamura, Mitsuo ^a   Hibi, Michiaki ^a   Yoshida, Katsuhiko ^a   Murakami, Fumihiko ^a   Tomita, Yasuhiro ^a   Ooshima, Hideki ^a   Murase, Mitsuya ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NAFAMSTAT MESILATE; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLOOD STORAGE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYSIS; FOREIGN BODY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030296360     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00634-0     Document Type: Article

References (19)

1. 1. Harker LA, Malpass TW, Bronson HE, Hessel EA II, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective-granule release. Blood 1980;56:824-34.
2. 2. Addonizio VP Jr, Smith JB, Strauss JF III, Colman RW, Edmunds LH. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with a bubble oxygenator. J Thorac Cardiovasc Surg 1980;79:91-6.
3. 3. Edmunds LH, Ellison N, Colman RW, et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982;83: 805-12.
4. 4. Kukuk O, Kwaan HC, Frederickson J, Wada L, Green D. Increased fibrinolysis in patients undergoing cardiopulmonary bypass operations. Am J Hematol 1986;23:223-9.
5. 5. Tice DA, Reed GE, Clauss RH, Worth MH. Hemorrhage due to fibrinolysis occurring with open heart surgery. J Thorac Cardiovasc Surg 1963;46:673-9.
6. 6. Musial J, Niewiarowski S, Hershock D, Morinelli TA, Colman RW, Edmunds LH Jr. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985;105:514-22.
7. 7. Gluszko P, Rucinski B, Musial J, et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987;252:H615-21.
8. 8. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981;661:342-5.
9. 9. Hitomi Y, Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 1982;69:262-7.
10. 10. Fujikawa K, Saito H. Contact activation. In: Screver CR, ed. The metabolic basis of inherited disease. New York: McGraw-Hill, 1989:2189-205.
11. 11. Von Segesser LK, Weiss BM, Garcia E, von Felten A, Turina MI. Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;103:790-9.
12. 12. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991;101:654-60.
13. 13. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate: 1. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984;35:203-27.
14. 14. Sundaram S, Gikakis N, Hack CE, et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996;75:76-82.
15. 15. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-α2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989;73:468-71.
16. 16. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate spares the blood during open heart surgery. Circulation 1993;88(Suppl 2):432-6.
17. 17. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Hemostasis 1985;15:164-8.
18. 18. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
19. 19. Nagaoka H, Innami R, Murayama F, et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg 1991;32:31-7.